BMO Capital Initiates Coverage on Tokai Pharmaceuticals Inc(NASDAQ:TKAI). The shares have been rated Outperform. The rating by BMO Capital was issued on Apr 12, 2016.
In a different note, On Feb 11, 2016, Oppenheimer said it Assumes its rating on Tokai Pharmaceuticals Inc. The shares have been rated ‘Outperform’ by the firm.
Tokai Pharmaceuticals Inc (TKAI) shares turned negative on Fridays trading session with the shares closing down -0.17 points or -2.24% at a volume of 1,25,768. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $7.86. The peak price level was also seen at $7.86 while the days lowest was $7.2. Finally the shares closed at $7.43. The 52-week high of the shares is $14.71 while the 52-week low is $4.93. According to the latest information available, the market cap of the company is $168 M.
Tokai Pharmaceuticals Inc(TKAI) last announced its earnings results on Mar 10, 2016 for Fiscal Year 2015 and Q4.Earnings per share were $-0.49.
Several Insider Transactions has been reported to the SEC. On Sep 22, 2015, John S. Mcbride (Chief Operating Officer) sold 13,500 shares at $14.01 per share price.Also, On Sep 8, 2015, Lee Kalowski (Chief Financial Officer) sold 4,668 shares at $13.13 per share price.On Jul 30, 2015, Jodie Pope Morrison (President and CEO) sold 12,564 shares at $13.70 per share price, according to the Form-4 filing with the securities and exchange commission.
Tokai Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate galeterone is a multi-targeted oral small molecule drug candidate that has advantages over existing prostate cancer therapies. The Company is focusing its initial development of galeterone on the treatment of patients with castration resistant prostate cancer (CRPC) whose prostate tumor cells express an altered androgen receptor that is truncated. Galeterone acts by disrupting the androgen receptor signaling pathway which is the primary pathway that drives prostate cancer growth. The Company is conducting a Phase II clinical trial of galeterone known as ARMOR2 trial for the treatment of multiple CRPC populations.